{
  "abstract": "Objectives To assess the attainment of remission and low disease activity (LDA) and their comparability between SLE and RA patients.Methods Data of 100 SLE patients with at least 3 consecutive outpatient visits between August, 2021, and January, 2023 were collected from outpatient records and matched in sex and age to 100 patients with seropositive RA. Standard documentation at every visit included SLE Disease Activity Index 2000 for SLE, Simplified Disease Activity Index for RA, as well as pain, patient global assessment (PtGA) and physician global assessment (PhGA) on visual analogue scales (VAS) for both. Remission and LDA were defined by SDAI cut-offs in RA and by Definition of Remission in SLE (DORIS) remission and Lupus Low Disease Activity State (LLDAS) in SLE.Results After matching, the SLE and RA patient cohorts were not significantly different with regard to sex, age, disease duration and number of visits. Remission or LDA were reached in 347 (88.5%) of 392 visits of SLE patients as compared to 354 (91.0%) of 389 visits of RA patients (p=0.2885). Remission was more common in SLE (79.3%) than RA (69.4%) data points (p=0.0018). PhGA was not significantly different between SLE and RA patients in low disease activity or remission, and only slightly higher in RA patients in remission (p=0.0002), while PtGA and pain were more variable and less associated with remission or active disease in SLE than in RA. C-reactive protein (CRP) was higher in active RA vs active SLE (p=0.0107), as expected, but erythrocyte sedimentation rates were not significantly different between SLE and RA in either remission, low disease activity, or active disease.Conclusions Proportions of visits in remission and of visits in remission or LDA were similar between SLE and RA patients. Despite differences between the diseases, and according differences between definitions, similarities in PhGA and acute phase reactants in either remission, low disease activity, or active disease, suggest that the SLE definitions for remission and LDA were successfully modelled on those of RA. The rates with which favorable states were attained supports the T2T approach in SLE, using LLDAS and DORIS remission.",
  "authors": [
    {
      "affiliations": [
        "University Medical Center and Faculty of Medicine TU Dresden, Department of Medicine III, Division of Rheumatology, Dresden, Germany"
      ],
      "name": "Konrad Hüther"
    },
    {
      "affiliations": [
        "University Medical Center and Faculty of Medicine TU Dresden, Department of Medicine III, Division of Rheumatology, Dresden, Germany"
      ],
      "name": "Nicolai Leuchten"
    },
    {
      "affiliations": [
        "University Medical Center and Faculty of Medicine TU Dresden, Department of Medicine III, Division of Rheumatology, Dresden, Germany"
      ],
      "name": "Martin Aringer"
    }
  ],
  "title": "PO:05:150 Treating-to-target (T2T): similar attainment of remission and low disease activity in patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA)",
  "uid": "89169818-9061-563c-b377-7d9057292303"
}